Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi, Gianluigi Marasi, Carlo Pasotti, Luigi Poletti, Andrea Rinaldi, Paola Preti

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Objective: This prospective, randomised, open-label, blinded-endpoint study was to compare the effects of the angiotensin II (Ang II) AT1 receptor antagonist valsartan with those of the ACE inhibitor enalapril on blood pressure (BP) and cognitive functions in elderly hypertensive patients. Methods: One hundred and forty-four patients aged 61-80 years with mild to moderate essential hypertension (DBF ≥95 mmHg and <110 mmHg at the end of a 2-week placebo run-in period) were randomly assigned to once daily (o.d.) treatment with valsartan 160 mg (n = 73) or enalapril 20 mg (n = 71) for 16 weeks. The patients were examined every 4 weeks during the study, with pre-dose BP (standard mercury sphygmomanometer, Korotkoff I and V) and heart rate (pulse palpation) being recorded at each visit. Cognitive function was evaluated at the end of the wash-out period and after 16 weeks of active treatment by means of five tests (verbal fluency, the Boston naming test, word list memory, word list recall and word list recognition). Results: Both valsartan and enalapril had a clear antihypertensive effect, but the former led to a slightly greater reduction in SBP/DBP at 16 weeks (18.6 ± 4.6/ 13.7 ± 4.0 mmHg vs 15.6 ± 5.1/10.9 ± 3.9 mmHg; P<0.01). Enalapril did not induce any significant changes in any of the cognitive function test scores; valsartan significantly increased the word list memory score (+11.8%; P <0.05 vs baseline and P <0.01 vs enalapril) and the word list recall score (+18.7%; P <0.05 vs baseline and P <0.01 vs enalapril), but not those of the other tests. Conclusion: These findings indicate that, in elderly hypertensive patients, 16 weeks of treatment with valsartan 160 mg o.d. is more effective than enalapril 20 mg o.d. in reducing BP, and (unlike enalapril) improves some of the components of cognitive function, particularly episodic memory.

Original languageEnglish
Pages (from-to)863-868
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume59
Issue number12
DOIs
Publication statusPublished - Feb 2004

Fingerprint

Valsartan
Enalapril
Cognition
Blood Pressure
Sphygmomanometers
Angiotensin Type 1 Receptor
Episodic Memory
Essential Hypertension
Palpation
Angiotensin Receptor Antagonists
Mercury
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents

Keywords

  • Cognitive functions
  • Enalapril
  • Valsartan

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. / Fogari, Roberto; Mugellini, Amedeo; Zoppi, Annalisa; Marasi, Gianluigi; Pasotti, Carlo; Poletti, Luigi; Rinaldi, Andrea; Preti, Paola.

In: European Journal of Clinical Pharmacology, Vol. 59, No. 12, 02.2004, p. 863-868.

Research output: Contribution to journalArticle

Fogari, Roberto ; Mugellini, Amedeo ; Zoppi, Annalisa ; Marasi, Gianluigi ; Pasotti, Carlo ; Poletti, Luigi ; Rinaldi, Andrea ; Preti, Paola. / Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. In: European Journal of Clinical Pharmacology. 2004 ; Vol. 59, No. 12. pp. 863-868.
@article{efefd93580be44d19b87f24d7d6eb0a4,
title = "Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension",
abstract = "Objective: This prospective, randomised, open-label, blinded-endpoint study was to compare the effects of the angiotensin II (Ang II) AT1 receptor antagonist valsartan with those of the ACE inhibitor enalapril on blood pressure (BP) and cognitive functions in elderly hypertensive patients. Methods: One hundred and forty-four patients aged 61-80 years with mild to moderate essential hypertension (DBF ≥95 mmHg and <110 mmHg at the end of a 2-week placebo run-in period) were randomly assigned to once daily (o.d.) treatment with valsartan 160 mg (n = 73) or enalapril 20 mg (n = 71) for 16 weeks. The patients were examined every 4 weeks during the study, with pre-dose BP (standard mercury sphygmomanometer, Korotkoff I and V) and heart rate (pulse palpation) being recorded at each visit. Cognitive function was evaluated at the end of the wash-out period and after 16 weeks of active treatment by means of five tests (verbal fluency, the Boston naming test, word list memory, word list recall and word list recognition). Results: Both valsartan and enalapril had a clear antihypertensive effect, but the former led to a slightly greater reduction in SBP/DBP at 16 weeks (18.6 ± 4.6/ 13.7 ± 4.0 mmHg vs 15.6 ± 5.1/10.9 ± 3.9 mmHg; P<0.01). Enalapril did not induce any significant changes in any of the cognitive function test scores; valsartan significantly increased the word list memory score (+11.8{\%}; P <0.05 vs baseline and P <0.01 vs enalapril) and the word list recall score (+18.7{\%}; P <0.05 vs baseline and P <0.01 vs enalapril), but not those of the other tests. Conclusion: These findings indicate that, in elderly hypertensive patients, 16 weeks of treatment with valsartan 160 mg o.d. is more effective than enalapril 20 mg o.d. in reducing BP, and (unlike enalapril) improves some of the components of cognitive function, particularly episodic memory.",
keywords = "Cognitive functions, Enalapril, Valsartan",
author = "Roberto Fogari and Amedeo Mugellini and Annalisa Zoppi and Gianluigi Marasi and Carlo Pasotti and Luigi Poletti and Andrea Rinaldi and Paola Preti",
year = "2004",
month = "2",
doi = "10.1007/s00228-003-0717-9",
language = "English",
volume = "59",
pages = "863--868",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

AU - Fogari, Roberto

AU - Mugellini, Amedeo

AU - Zoppi, Annalisa

AU - Marasi, Gianluigi

AU - Pasotti, Carlo

AU - Poletti, Luigi

AU - Rinaldi, Andrea

AU - Preti, Paola

PY - 2004/2

Y1 - 2004/2

N2 - Objective: This prospective, randomised, open-label, blinded-endpoint study was to compare the effects of the angiotensin II (Ang II) AT1 receptor antagonist valsartan with those of the ACE inhibitor enalapril on blood pressure (BP) and cognitive functions in elderly hypertensive patients. Methods: One hundred and forty-four patients aged 61-80 years with mild to moderate essential hypertension (DBF ≥95 mmHg and <110 mmHg at the end of a 2-week placebo run-in period) were randomly assigned to once daily (o.d.) treatment with valsartan 160 mg (n = 73) or enalapril 20 mg (n = 71) for 16 weeks. The patients were examined every 4 weeks during the study, with pre-dose BP (standard mercury sphygmomanometer, Korotkoff I and V) and heart rate (pulse palpation) being recorded at each visit. Cognitive function was evaluated at the end of the wash-out period and after 16 weeks of active treatment by means of five tests (verbal fluency, the Boston naming test, word list memory, word list recall and word list recognition). Results: Both valsartan and enalapril had a clear antihypertensive effect, but the former led to a slightly greater reduction in SBP/DBP at 16 weeks (18.6 ± 4.6/ 13.7 ± 4.0 mmHg vs 15.6 ± 5.1/10.9 ± 3.9 mmHg; P<0.01). Enalapril did not induce any significant changes in any of the cognitive function test scores; valsartan significantly increased the word list memory score (+11.8%; P <0.05 vs baseline and P <0.01 vs enalapril) and the word list recall score (+18.7%; P <0.05 vs baseline and P <0.01 vs enalapril), but not those of the other tests. Conclusion: These findings indicate that, in elderly hypertensive patients, 16 weeks of treatment with valsartan 160 mg o.d. is more effective than enalapril 20 mg o.d. in reducing BP, and (unlike enalapril) improves some of the components of cognitive function, particularly episodic memory.

AB - Objective: This prospective, randomised, open-label, blinded-endpoint study was to compare the effects of the angiotensin II (Ang II) AT1 receptor antagonist valsartan with those of the ACE inhibitor enalapril on blood pressure (BP) and cognitive functions in elderly hypertensive patients. Methods: One hundred and forty-four patients aged 61-80 years with mild to moderate essential hypertension (DBF ≥95 mmHg and <110 mmHg at the end of a 2-week placebo run-in period) were randomly assigned to once daily (o.d.) treatment with valsartan 160 mg (n = 73) or enalapril 20 mg (n = 71) for 16 weeks. The patients were examined every 4 weeks during the study, with pre-dose BP (standard mercury sphygmomanometer, Korotkoff I and V) and heart rate (pulse palpation) being recorded at each visit. Cognitive function was evaluated at the end of the wash-out period and after 16 weeks of active treatment by means of five tests (verbal fluency, the Boston naming test, word list memory, word list recall and word list recognition). Results: Both valsartan and enalapril had a clear antihypertensive effect, but the former led to a slightly greater reduction in SBP/DBP at 16 weeks (18.6 ± 4.6/ 13.7 ± 4.0 mmHg vs 15.6 ± 5.1/10.9 ± 3.9 mmHg; P<0.01). Enalapril did not induce any significant changes in any of the cognitive function test scores; valsartan significantly increased the word list memory score (+11.8%; P <0.05 vs baseline and P <0.01 vs enalapril) and the word list recall score (+18.7%; P <0.05 vs baseline and P <0.01 vs enalapril), but not those of the other tests. Conclusion: These findings indicate that, in elderly hypertensive patients, 16 weeks of treatment with valsartan 160 mg o.d. is more effective than enalapril 20 mg o.d. in reducing BP, and (unlike enalapril) improves some of the components of cognitive function, particularly episodic memory.

KW - Cognitive functions

KW - Enalapril

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=1542616497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542616497&partnerID=8YFLogxK

U2 - 10.1007/s00228-003-0717-9

DO - 10.1007/s00228-003-0717-9

M3 - Article

VL - 59

SP - 863

EP - 868

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 12

ER -